What is the Lantheus Holdings, Inc. stock price forecast?

Lantheus Holdings, Inc. is currently trading at $104.52. View real-time AI analysis on Alpha Lenz.

What is Lantheus Holdings, Inc. insider trading activity?

View the latest insider trading data for Lantheus Holdings, Inc. on Alpha Lenz.

What is Lantheus Holdings, Inc.'s P/E ratio?

Lantheus Holdings, Inc.'s P/E ratio is 30.2.

Lantheus Holdings, Inc.

NASDAQ · LNTH

$104.52+0.20(+0.19%)Pre-market

Ask about Lantheus Holdings, Inc.'s future dividend policy...

Alpha Chat Insight

“Lantheus Holdings, Inc. trades at a P/E of 30.2 (premium valuation) with strong ROE of 21.4%. 3Y revenue CAGR of 18.1% highlights clear growth momentum.”

Ask for details →

Company Overview

Lantheus Holdings, Inc. is a leading healthcare company specializing in radiopharmaceuticals, with a core focus on developing, manufacturing, and distributing advanced diagnostic and therapeutic medical products. Its portfolio features precision imaging agents and diagnostic tools such as Pylarify, Definity, TechneLite, Cardiolite, Neurolite, and Xenon Xe-133 Gas, which are integral in fields like oncology, urology, nuclear medicine, cardiology, and radiology. The company also has an active pipeline, including candidates targeting neuroendocrine tumors and Alzheimer’s disease, reflecting ongoing innovation and research commitment. Lantheus Holdings caters to a diverse client base of hospitals, diagnostic testing facilities, and clinics globally, supporting clinicians in detecting and managing diseases such as cancer and cardiovascular conditions. With its global presence and strategic industry partnerships, Lantheus Holdings plays a significant role in driving advancements in medical imaging and targeted diagnostics, underlining its importance in the broader healthcare technology sector.

CEOMr. Brian A. Markison

Websitehttps://www.lantheus.com

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Employees808

Company Statistics

FY 2025

Profile

$7.05BMarket Cap

$1.54BRevenue

0.00Shares Out

808Employees

Margins

61.10%Gross

26.53%EBITDA

20.47%Operating

20.35%Pre-Tax

15.15%Net

Valuation

30.20P/E

6.47P/B

4.58EV/Sales

17.88EV/EBITDA

20.23P/FCF

Growth (CAGR)

18.13%Rev 3Yr

35.35%Rev 5Yr

105.82%Op Inc 3Yr

N/AOp Inc 5Yr

102.64%Net Inc 3Yr

N/ANet Inc 5Yr

Returns

11.10%ROA

21.45%ROE

15.85%ROIC

Financial Health

$359.12MCash & Cash Equivalents

$778.48MNet Debt

104.39%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Lantheus Holdings, Inc. trades at a P/E of 30.2 (premium valuation) with strong ROE of 21.4%. 3Y revenue CAGR of 18.1% highlights clear growth momentum.”

Ask for details →

Frequently Asked Questions

Lantheus Holdings, Inc. (ticker: LNTH) is a company listed on NASDAQ in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 808 employees. Market cap is $7.1B.

The current price is $104.52 with a P/E ratio of 30.2x and P/B of 6.47x.

ROE is 21.45% and operating margin is 20.47%. Annual revenue is $1.5B.